Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta Analysis Journal of Clinical Question Current Strategies in Managing Obesity STRIVE Obesity CagriSema misses noninferiority vs tirzepatide in REDEFINE 4; Novo Nordisk shares fall 15% iPharmaCenter Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Cagrilintide, an amylin analogue, is a promising medication for weight loss by enhancing satiety, delaying gastric emptying, and suppressing appetite. In my patients, I have also seen increased